tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2016-94-11-7-15tiblj-950Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЛИКВИДАЦИЯ ТУБЕРКУЛЕЗА - НОВАЯ СТРАТЕГИЯ ВОЗ В ЭРУ ЦЕЛЕЙ УСТОЙЧИВОГО РАЗВИТИЯ, ВКЛАД РОССИЙСКОЙ ФЕДЕРАЦИИEND TB – THE NEW WHO STRATEGY IN THE SDG ERA* , AND THE CONTRIBUTIONS FROM THE RUSSIAN FEDERATIONРавильонеМ. К.RaviglioneM. C.

Руководитель,

Программа ВОЗ по борьбе с туберкулезом 20, Avenue Appia, 1211 Geneva 27

Director,

WHO Global TB Programme 20, Avenue Appia, 1211 Geneva 27

raviglionem@who.intКоробицынА. А.KorobitsynA. A.

Технический сотрудник,

Программа ВОЗ по борьбе с туберкулезом 20, Avenue Appia, 1211 Geneva 27

Technical Officer,

WHO Global TB Programme 20, Avenue Appia, 1211 Geneva 27

korobitsyna@who.intГлобальная программа по борьбе с туберкулезом, ВОЗШвейцарияGlobal Tuberculosis Programme, WHOSwitzerland2016011120169411715Copyright © Равильоне М.К., Коробицын А.А., 20162016Равильоне М.К., Коробицын А.А.Raviglione M.C., Korobitsyn A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/950

This article is written to update tuberculosis (TB) experts in the Russian Federation about the most recent data on the global TB situation, the progress in global TB care and control efforts, the challenges ahead, and the response expected by all countries. In particular, the article will detail the new End TB Strategy that the World Health Organization (WHO) is promoting for the new era of the Sustainable Development Goals 2016-2030 after the World Health Assembly approved it in a resolution during its 2014 meeting. The Russian Federation, with its extraordinary resources and knowledge needs to contribute to the roll-out of the new Strategy, both nationally and internationally. For this, the Ministerial Conference called by the Russian Federation Government to be held in Moscow on 16-17 November 2017 will play a crucial role in calling for the political attention necessary at the highest governmental levels in all high-burden countries, with an ultimate aim to raise the struggle against TB in the heads-of-state agenda.

оказание помощиликвидация туберкулезаcare provisionEnd TBReferencesGlobal Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva: World Health Organization, 2016.Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva, World Health Organization, 2016.M. Raviglione. Ending TB - Global situation and a new strategy in the SDG era. Presentationatthe 7th ConferenceoftheUnionEuropeanRegionM. Raviglione. Ending TB – Global situation and a new strategy in the SDG era. Presentation at the 7th Conference of the Union European Region. 3. The Global Fund. http://www.theglobalfund.org/en/tuberculosis/The Global Fund. http://www.theglobalfund.org/en/tuberculosis/Uplekar M. Public-private mix for tuberculosis care and prevention. What progress? What prospects? Int. J. Tuberc. Lung Dis., 2016, vol. 20(11), pp. 1424-1429.Uplekar M. Public-private mix for tuberculosis care and prevention. What progress? What prospects? // Int. J. Tuberc. Lung Dis. - 2016. - Vol. 20, № 11. - Р. 1424-1429.UNAIDS Fact sheet, 2016. http://www.unaids.org/en/resources/fact-sheet 6. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. WHO/ HTM/TB/2012.1. Geneva, World Health Organization, 2012.UNAIDS Fact sheet, 2016http://www.unaids.org/en/resources/fact-sheetTanimura T., Jaramillo E., Weil D., Raviglione M., Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur. Respir. J ., 2014, vol. 43, pp. 1763-1775.WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. WHO/ HTM/TB/2012.1. Geneva: World Health Organization; 2012.The End TB strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. The official text approved by the Sixty seventh World Health Assembly, May 2014.Tanimura T., Jaramillo E., Weil D. et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review // Eur. Respir. J. - 2014. - Vol. 43. - P. 1763-1775.Implementing The End TB strategy: The Essentials. WHO/HTM/TB/2015.31. Geneva, World Health Organization, 2015.The End TB strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. The official text approved by the Sixty seventh World Health Assembly, May 2014.Grzybowski S., Styblo K., Dorken E. Tuberculosis in Eskimos. Tubercle, 1976, suppl. 57, pp 1-58.Implementing The End TB strategy: The Essentials. WHO/HTM/TB/2015.31. Geneva: World Health Organization, 2015.Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16, Geneva, World Health Organization, 2013.Grzybowski S., Styblo K., Dorken E. Tuberculosis in Eskimos // Tubercle. - 1976. - Suppl. 57. - P. 1-58.Implementing tuberculosis diagnostics. Policy framework. WHO/HTM/TB/2015.11. Geneva, World Health Organization, 2015.Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance:Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16 Geneva, World Health Organization, 2013.The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. Policy guidance. 2016 update. WHO/HTM/TB/2016.12. Geneva, World Health Organization, 2016.Implementing tuberculosis diagnostics. Policy framework. WHO/HTM/TB/2015.11. Geneva: World Health Organization, 2015.The use of molecular line probe assays for the detection of resistance to second-line anti-TB drugs. Policy guidance. WHO/HTM/TB/2016.07. Geneva, World Health Organization, 2016.The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. Policy guidance. 2016 update. WHO/HTM/TB/2016.12. Geneva: World Health Organization, 2016.WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/2016.04 Geneva, World Health Organization, 2016.The use of molecular line probe assays for the detection of resistance to second-line anti-TB drugs. Policyguidance. WHO/HTM/TB/2016.07. Geneva: World Health Organization, 2016.Getahun H., Matteelli A., Abubakar I., Aziz M.A., Baddeley A., Barreira D. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J., 2015, Dec., vol. 46(6), pp. 1563-76.WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/2016.04 Geneva: World Health Organization, 2016.Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, World Health Organization, 2015.Getahun H., Matteelli A., Abubakar I. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries // Eur. Respir. J. - 2015. - Vol. 46, № 6. - Р. 1563-1576.Lönnroth K., Jaramillo E., Williams B.G., Dye C., Raviglione M. Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Social Science & Medicine, vol. 68, 2009, pp. 2240-2246.Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World Health Organization, 2015.Lönnroth K., Raviglione M. The WHO’s new End TB Strategy in the post-2015 era of the sustainable Development Goals. Trans. R. Soc. Trop. Med., Hyg., 2016, vol. 110, pp.148–150.Lönnroth K., Jaramillo E., Williams B. G. et al. Drivers of tuberculosis epidemics: The role of risk factors and social determinants // Social Science & Medicine. - 2009. - Vol. 68. - P. 2240-2246.Siroka A., Ponce N.A., Lönnroth K. Association between spending on social protection and tuberculosis burden: a global analysis. Lancet Infect. Dis., 2016, vol. 16, pp. 473-79.Lönnroth K., Raviglione M. The WHO’s new End TB Strategy in the post-2015 era of the sustainable Development Goals // Trans. R. Soc. Trop. Med. Hyg. - 2016. - Vol. 110. - P. 148-150.Boccia D., Pedrazzoli D., Wingfield T., Jaramillo E., Lönnroth K., Lewis J. et all. Towards cash transfer interventions for tuberculosis prevention, care and control: key operational challenges and research priorities. BMC Infectious Diseases, 2016, vol.16, pp. 307.Siroka A., Ponce N. A., Lönnroth K. Association between spending on social protection and tuberculosis burden: a global analysis // Lancet Infect. Dis. - 2016. - Vol. 16. - P. 473-479.A WHO/The Union Monograph on TB and Tobacco Control. Joining efforts to control two related epidemics. WHO/HTM/TB/2007.390. Geneva, World Health Organization, 2007.Boccia D., Pedrazzoli D., Wingfield T. et al. Towards cash transfer interventions for tuberculosis prevention, care and control: key operational challenges and research priorities // BMC Infectious Diseas. -2016. - Vol. 16. - P. 307.Creswell J., Raviglione M., Ottmani S., Migliori G.B., Uplekar M., Blanc L., Sotgiu G., Lönnroth K. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur. Respir. J., 2011, vol. 37, pp. 1269-1282.A WHO/The Union Monograph on TB and Tobacco Control. Joining efforts to control two related epidemics. WHO/HTM/TB/2007.390. Geneva: World Health Organization, 2007.Lönnroth K., Williams B.G., Jaramillo E., Stadlin S., Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health, 2008, vol. 8, pp. 289.Creswell J., Raviglione M., Ottmani S. et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities // Eur. Respir. J. - 2011. - Vol. 37. - P. 1269-1282.Lönnroth K., Roglic G., Harries A.D. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol., 2014, vol. 2, pp. 730-39.Lönnroth K., Williams B. G., Jaramillo E. et al. Alcohol use as a risk factor for tuberculosis - a systematic review // BMC Public Health. - 2008. - Vol. 8. - P. 289.Precision Medicine Initiative. NIH-USA. https://www.nih.gov/precision-medicine-initiative-cohort-programLönnroth K., Roglic G., Harries A. D. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice // Lancet Diabetes Endocrinol. - 2014. - Vol. 2. - P. 730-739.Digital health for the End TB Strategy - an agenda for action. WHO/HTM/TB/2015.21. Geneva, World Health Organization, 2015.Precision Medicine Initiative, NIH-USA, https://www.nih.gov/precision-medicine-initiative-cohort-programFalzon D., Timimi H., Kurosinski P., Migliori G.B., Van Gemert W., Denkinger C. et al. Digital Health for the End TB Strategy: developing priority products and making them work. Eur. Respir. J., 2016, pp. 29-45.Digital health for the End TB Strategy - an agenda for action. WHO/HTM/TB/2015.21. Geneva: World Health Organization, 2015.Falzon D., Raviglione M. The Internet of Things to come: digital technologies and the End TB Strategy. BMJ, 2016, DOI: 10.1136/bmjgh-2016-000038.Falzon D., Timimi H., Kurosinski P. et al. Digital Health for the End TB Strategy: developing priority products and making them work // Eur. Respir. J. - 2016. - P. 29-45.GLI guide to the connectivity solutions, Geneva, 2016.Falzon D., Raviglione M. The Internet of Things to come: digital technologies and the End TB Strategy. BMJ. 2016 DOI: 10.1136/bmjgh-2016-000038.Falzon D., Raviglione M. The Internet of Things to come: digital technologies and the End TB Strategy. BMJ. 2016 DOI: 10.1136/bmjgh-2016-000038.GLI guide to the connectivity solutions, Geneva, 2016.GLI guide to the connectivity solutions, Geneva, 2016.

The authors declare that there are no conflicts of interest present.